BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 20196816)

  • 1. Immune surveillance of human cancer: if the cytotoxic T-lymphocytes play the music, does the tumoral system call the tune?
    Hamaï A; Benlalam H; Meslin F; Hasmim M; Carré T; Akalay I; Janji B; Berchem G; Noman MZ; Chouaib S
    Tissue Antigens; 2010 Jan; 75(1):1-8. PubMed ID: 20196816
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor resistance to CD8+ T cell-based therapeutic vaccination.
    Huang Y; Shah S; Qiao L
    Arch Immunol Ther Exp (Warsz); 2007; 55(4):205-17. PubMed ID: 17659376
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MHC class I antigens, immune surveillance, and tumor immune escape.
    Garcia-Lora A; Algarra I; Garrido F
    J Cell Physiol; 2003 Jun; 195(3):346-55. PubMed ID: 12704644
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The 'kiss of death' by dendritic cells to cancer cells.
    Chan CW; Housseau F
    Cell Death Differ; 2008 Jan; 15(1):58-69. PubMed ID: 17948029
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Cytotoxic T lymphocytes: role in immunosurveillance and in immunotherapy].
    Benchetrit F; Gazagne A; Adotevi O; Haicheur N; Godard B; Badoual C; Fridman WH; Tartour E
    Bull Cancer; 2003; 90(8-9):677-85. PubMed ID: 14609756
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor resistance to specific lysis: a major hurdle for successful immunotherapy of cancer.
    Chouaib S; Meslin F; Thiery J; Mami-Chouaib F
    Clin Immunol; 2009 Jan; 130(1):34-40. PubMed ID: 19013109
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune selection in murine tumors. Ph.d thesis.
    Svane IM; Engel AM
    APMIS Suppl; 2003; (106):1-46. PubMed ID: 12739251
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gap junction communication between autologous endothelial and tumor cells induce cross-recognition and elimination by specific CTL.
    Benlalam H; Jalil A; Hasmim M; Pang B; Tamouza R; Mitterrand M; Godet Y; Lamerant N; Robert C; Avril MF; Neefjes J; Tursz T; Mami-Chouaib F; Kieda C; Chouaib S
    J Immunol; 2009 Mar; 182(5):2654-64. PubMed ID: 19234159
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cellular mechanisms of lymphocyte-mediated lysis of tumor cells.
    Arancia G; Malorni W; Donelli G
    Ann Ist Super Sanita; 1990; 26(3-4):369-84. PubMed ID: 2151107
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor rejection antigens and tumor specific cytotoxic T lymphocytes.
    Toes RE; Offringa R; Feltkamp MC; Visseren MJ; Schoenberger SP; Melief CJ; Kast WM
    Behring Inst Mitt; 1994 Jul; (94):72-86. PubMed ID: 7998917
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Helper T cells against tumor-associated antigens (TAA): preferential induction of helper T cell activities involved in anti-TAA cytotoxic T lymphocyte and antibody responses.
    Fujiwara H; Yoshioka T; Shima J; Kosugi A; Itoh K; Hamaoka T
    J Immunol; 1986 Apr; 136(7):2715-9. PubMed ID: 3005417
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumors with reduced expression of a cytotoxic T lymphocyte recognized antigen lack immunogenicity but retain sensitivity to lysis by cytotoxic T lymphocytes.
    Koeppen H; Acena M; Drolet A; Rowley DA; Schreiber H
    Eur J Immunol; 1993 Nov; 23(11):2770-6. PubMed ID: 8223853
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor-host immune interactions and dendritic cell dysfunction.
    Yang L; Carbone DP
    Adv Cancer Res; 2004; 92():13-27. PubMed ID: 15530555
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cell-mediated immune responses to syngeneic tumors. I. Identification of two distinct CTL effector pathways which differ in antigen specificity, genetic regulation, and cell surface phenotype.
    Lynch DH; Daynes RA; Hodes RJ
    J Immunol; 1986 Feb; 136(4):1521-7. PubMed ID: 2418117
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A model for CD8+ CTL tumor immunosurveillance and regulation of tumor escape by CD4 T cells through an effect on quality of CTL.
    Matsui S; Ahlers JD; Vortmeyer AO; Terabe M; Tsukui T; Carbone DP; Liotta LA; Berzofsky JA
    J Immunol; 1999 Jul; 163(1):184-93. PubMed ID: 10384115
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A fresh look at tumor immunosurveillance and immunotherapy.
    Smyth MJ; Godfrey DI; Trapani JA
    Nat Immunol; 2001 Apr; 2(4):293-9. PubMed ID: 11276199
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MHC class I restricted T cells and immune surveillance against transplanted ultraviolet light-induced tumors.
    Ward PL; Schreiber H
    Semin Cancer Biol; 1991 Oct; 2(5):321-8. PubMed ID: 1837738
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytotoxic T cell clones against human autologous cancers: analysis of target antigen and the mechanism of specific target cell destruction.
    Kikuchi K; Okubo M; Sato T; Sato N
    Princess Takamatsu Symp; 1988; 19():303-13. PubMed ID: 3269362
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vaccination with a recombinant protein encoding the tumor-specific antigen NY-ESO-1 elicits an A2/157-165-specific CTL repertoire structurally distinct and of reduced tumor reactivity than that elicited by spontaneous immune responses to NY-ESO-1-expressing Tumors.
    Bioley G; Guillaume P; Luescher I; Bhardwaj N; Mears G; Old L; Valmori D; Ayyoub M
    J Immunother; 2009; 32(2):161-8. PubMed ID: 19238015
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The HER2/neu-derived peptide p654-662 is a tumor-associated antigen in human pancreatic cancer recognized by cytotoxic T lymphocytes.
    Peiper M; Goedegebuure PS; Linehan DC; Ganguly E; Douville CC; Eberlein TJ
    Eur J Immunol; 1997 May; 27(5):1115-23. PubMed ID: 9174600
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.